356 related articles for article (PubMed ID: 19798417)
1. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.
Lee CH; Subramanian S; Beck AH; Espinosa I; Senz J; Zhu SX; Huntsman D; van de Rijn M; Gilks CB
PLoS One; 2009 Oct; 4(10):e7314. PubMed ID: 19798417
[TBL] [Abstract][Full Text] [Related]
2. Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.
Pradhan M; Risberg BA; Tropé CG; van de Rijn M; Gilks CB; Lee CH
BMC Cancer; 2010 Sep; 10():493. PubMed ID: 20843305
[TBL] [Abstract][Full Text] [Related]
3. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma.
Tone AA; Begley H; Sharma M; Murphy J; Rosen B; Brown TJ; Shaw PA
Clin Cancer Res; 2008 Jul; 14(13):4067-78. PubMed ID: 18593983
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
McAlpine JN; Porter H; Köbel M; Nelson BH; Prentice LM; Kalloger SE; Senz J; Milne K; Ding J; Shah SP; Huntsman DG; Gilks CB
Mod Pathol; 2012 May; 25(5):740-50. PubMed ID: 22282309
[TBL] [Abstract][Full Text] [Related]
6. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].
Zhang Q; He XJ; Ma LP; Li N; Yang J; Cheng YX; Cui H
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
8. Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer.
Yu Z; Kim J; He L; Creighton CJ; Gunaratne PH; Hawkins SM; Matzuk MM
Biol Reprod; 2014 Nov; 91(5):113. PubMed ID: 25273528
[TBL] [Abstract][Full Text] [Related]
9. Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
Reyes MC; Arnold AG; Kauff ND; Levine DA; Soslow RA
Mod Pathol; 2014 Oct; 27(10):1405-11. PubMed ID: 24577588
[TBL] [Abstract][Full Text] [Related]
10. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET
J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084
[TBL] [Abstract][Full Text] [Related]
12. Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue.
Nam EJ; Kim S; Lee TS; Kim HJ; Lee JY; Kim SW; Kim JH; Kim YT
Oncotarget; 2016 Oct; 7(43):70524-70534. PubMed ID: 27655640
[TBL] [Abstract][Full Text] [Related]
13. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
14. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
[TBL] [Abstract][Full Text] [Related]
16. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
Piek JM; Torrenga B; Hermsen B; Verheijen RH; Zweemer RP; Gille JJ; Kenemans P; van Diest PJ; Menko FH
Fam Cancer; 2003; 2(2):73-8. PubMed ID: 14574155
[TBL] [Abstract][Full Text] [Related]
17. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
Press JZ; De Luca A; Boyd N; Young S; Troussard A; Ridge Y; Kaurah P; Kalloger SE; Blood KA; Smith M; Spellman PT; Wang Y; Miller DM; Horsman D; Faham M; Gilks CB; Gray J; Huntsman DG
BMC Cancer; 2008 Jan; 8():17. PubMed ID: 18208621
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA expression profiles in serous ovarian carcinoma.
Nam EJ; Yoon H; Kim SW; Kim H; Kim YT; Kim JH; Kim JW; Kim S
Clin Cancer Res; 2008 May; 14(9):2690-5. PubMed ID: 18451233
[TBL] [Abstract][Full Text] [Related]
19. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Škapa P; Dundr P
Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
[TBL] [Abstract][Full Text] [Related]
20. Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers.
George SH; Greenaway J; Milea A; Clary V; Shaw S; Sharma M; Virtanen C; Shaw PA
J Pathol; 2011 Sep; 225(1):106-17. PubMed ID: 21744340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
